Phylogica Investor Briefing‌‌‌‌‌‌‌‌‌

August 2017

Stephanie Unwin, Chief Executive Officer

Disclaimer

The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) ['Phylogica']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Phylogica and should not be relied upon as an independent source of information. Please contact Phylogica and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Phylogica. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2

Corporate profile

Phylogica stock price, AUD Directors

0.06

0.04

0.02

0

FY14

FY15

FY16

FY17

Stephanie Unwin

Dr Robert Hayes, PhD Dr Bernard Hockings Dr Rick Kendall

Dr Paul Watt

Dr Rohan Hockings

Chief Executive Officer Executive Director

Non-Executive Director Non-Executive Director Non-Executive Director

Alternate Non-Executive Director

Research Coverage

Bioshares Euroz

NDF research ShareAnalysis Wright Investors

Major shareholders, %

Bernard Edward Hockings Sietsma Holdings Pty Ltd Australian Land Pty Ltd Tony Barton and Assoc Masali Pty Ltd

27.50

6.93

7.55

4.50

3.67

Capital structure

Issued ordinary shares (bn) 2.12B

Unlisted options (mn) 47.7m Current1 market capitisation (mn) 95.44AUD Current1 share price 4.4c AUD Past 12 months1 average daily trading 1.5-5.3c AUD

1 Current as of 01/08/2017 and past 12 months covering 01/08/2016 to 01/08/17 SOURCE: ASX

Highly valuable intracellular target space remains untapped 80% of drug targets are inside cells but only 10% of such targets are druggable Phylogica's FPP platform finds peptides which can break through the cell membrane (Endosomal escape)

Distribution of drug targets

Market for biologics drugs

Outside cells

Cell membrane Small molecules

Biologics

$220B

20%

10%

70% $0

Phylogica's ambition: expand the druggable intracellular landscape by >10-fold with Functional Penetrating Phylomers (FPPs) - Phylogica's proprietary cell penetrating peptides

4

Phylogica Limited published this content on 21 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 August 2017 00:52:04 UTC.

Original documenthttp://phylogica.com/wp-content/uploads/2017/08/170821_Phylogica-Investor-Briefing-August-2017-Amended_1703209.pdf

Public permalinkhttp://www.publicnow.com/view/CF655B7A2DE1CD92A4CE129DFD259A8EDCF4E20D